Mythri Mudireddy

Blue Mountain College — United States

Medicine · Health Sciences

21h-index2.2kcitations51works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment(46), Acute Myeloid Leukemia Research(32), Chronic Myeloid Leukemia Treatments(14), Eosinophilic Disorders and Syndromes(12), Kruppel-like factors research(12)

Publications51 total

Acquired hemophilia A associated with amlodipine use in a hypertensive patient: A case report
Blood·2025
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
Mayo Clinic Proceedings·2019· 151 cited
Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
Blood Cancer Journal·2019· 69 citedOpen Access
The germline <i>JAK2</i> GGCC (46/1) haplotype and survival among 414 molecularly‐annotated patients with primary myelofibrosis
American Journal of Hematology·2018· 13 citedOpen Access
Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies
Blood·2018· 1 cited
Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study
Blood·2018· 2 cited
20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients
Blood·2018· 1 cited
Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger
Blood·2018
Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events
Blood·2018
Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)
Blood·2018· 7 cited
3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
Blood·2018· 32 cited
Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates
Blood·2018
The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis
Blood·2018
Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
Blood Cancer Journal·2018· 9 citedOpen Access
Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
Blood Advances·2018· 26 citedOpen Access
Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis
American Journal of Hematology·2018· 10 citedOpen Access
Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?
Clinical Genitourinary Cancer·2018· 1 cited
Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information
Mayo Clinic Proceedings·2018· 24 cited
Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
Blood Cancer Journal·2018· 34 citedOpen Access
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Leukemia·2018· 284 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Ayalew Tefferi(49), Naseema Gangat(47), Animesh Pardanani(46), Curtis A. Hanson(41), Rhett P. Ketterling(40), Terra L. Lasho(32), Christy M. Finke(24), Maura Nicolosi(22), Mrinal M. Patnaik(18), Natasha Szuber(16), Kebede H. Begna(14), Rangit Vallapureddy(14), Domenico Penna(13), Sahrish Shah(9), Paola Guglielmelli(8), Alessandro M. Vannucchi(8), Michelle A. Elliott(8), Daniela Barraco(8), C. Christopher Hook(4), Sravanthi Lavu(4)